Guardant Health's (GH) Shield colorectal cancer screening test will be made available to physicians and patients served by Quest Diagnostics (DGX) in the US, the companies said Wednesday.
Under the companies' multiyear collaboration, Quest's physician clients will be able to directly order Shield starting Q1 of 2026, according to a joint statement.
Shares of Guardant and Quest were each up more than 2% in recent premarket activity Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.